Olaf Schmechel
06 January 2021

GSK Stockmann advises AviaRent on the sale of 10 care homes from the CareVision I fund

GSK Stockmann has advised AviaRent Invest AG on the sale of a real estate portfolio consisting of 10 care homes to Hemsö Fastighets AB, providing comprehensive legal and tax advice.

As part of an asset deal regarding its CareVision I fund, AviaRent has sold 10 care home properties to Swedish real estate company Hemsö Fastighets AB. The total transaction volume amounts to over EUR 90 million.

The properties are located in six federal states, in Saxony, Baden-Württemberg, North Rhine-Westphalia, Lower Saxony, Brandenburg and Schleswig-Holstein, and are managed by nine different operators. Overall, the ten properties, built between 1900 and 2012, comprise 907 beds, around 73% of which are single rooms, as well as 128 assisted living apartments.

AviaRent was advised on the legal and tax aspects involved in the sale of the properties by a GSK Stockmann team surrounding partner Olaf Schmechel. In addition to transaction structuring, the consultation services included contract drafting and negotiation. GSK Stockmann also assisted in tax issues. In doing so, the firm was able to contribute its special expertise in the healthcare sector. GSK Stockmann has many years of experience in all aspects of healthcare real estate with a focus on nursing home properties.

Since 2009, GSK Stockmann has regularly been advising AviaRent on the acquisition of nursing care properties, facilities for age-appropriate and assisted living as well as micro-living properties.

Advisers to AviaRent:

GSK Stockmann: Olaf Schmechel (lead, Real Estate), Dominik Berka (Tax); Associates: Emily Arkhurst (Real Estate)

Print


Press contact
presse@gsk.de
+49 30 203907-7763

Back

GSK Updates
  • 17 May 2023

    GSK Update: German Tax Aspects for Inbound Investments

    Read more
  • 05 May 2023

    GSK Update: Real Estate Investments in Germany from a Tax Perspective

    Read more
  • 04 April 2023

    GSK Update: European Union institutions agree on a standard for EU Green Bonds – Current developments

    Read more
Contact person
Olaf Schmechel

Dr. Olaf Schmechel

Partner*

+49 30 203907-15

olaf.schmechel@gsk.de

For reasons of better readability, we use the gender-neutral generic masculine. However, the information expressly refers to all genders.

CO2 Neutral